What are the indications, adverse effects, and contraindications of the medication?

Medication Indications, Adverse Effects, and Contraindications

The question lacks specificity about which medication is being asked about, but based on the provided evidence, I'll address the most clinically relevant medications with comprehensive safety profiles from the guidelines.

Weight Management Medications

GLP-1 Receptor Agonists (Liraglutide 3.0 mg, Semaglutide 2.4 mg)

Indications:

• Chronic weight management in adults with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities 1, 2
• Type 2 diabetes management (at lower doses) 3

Common Adverse Effects:

• Gastrointestinal: nausea, vomiting, diarrhea, esophageal reflux (most common) 1, 2
• Injection site reactions
• Elevated heart rate
• Hypoglycemia (when combined with insulin or sulfonylureas) 2

Contraindications and Safety Concerns:

• Absolute contraindications: Personal or family history of medullary thyroid cancer or MEN 2 syndrome 1, 2, 4
• Pregnancy and breastfeeding 1, 2
• Pancreatitis (discontinue if suspected; causality not established but reported in trials) 1, 2
• Use caution in kidney disease due to risk of acute kidney injury from dehydration 2
• Black box warning: Risk of thyroid C-cell tumors in rodents (human relevance undetermined) 1, 2

Critical caveat: Liraglutide 1.8 mg may reduce efficacy of oral hormonal contraceptives due to delayed gastric emptying—switch to non-oral contraceptive or add barrier method for 4 weeks after initiation and each dose escalation 2

---

Phentermine/Topiramate ER

Indications:

• Chronic weight management 1, 2, 4

Common Adverse Effects:

• Constipation, paresthesia, insomnia, nasopharyngitis, xerostomia 1, 2
• Cognitive impairment (concentration and memory issues) 4
• Decreased bicarbonate, anxiety 4

Contraindications:

• Pregnancy (topiramate is teratogenic) 1, 2, 4
• Hyperthyroidism 2, 4
• Acute angle-closure glaucoma 1, 2, 4
• Concurrent MAOI use (allow ≥14 days between discontinuation) 1, 2, 4
• Uncontrolled hypertension 4

Monitoring Requirements:

• βHCG before initiating, then monthly self-testing at home 4
• Monitor electrolytes and creatinine before and during treatment 4
• Monitor for depression or worsening depression 2
• Hypokalemia risk (especially with HCTZ or furosemide) 4

Important: Do not discontinue 15 mg/92 mg dose abruptly—taper over at least 1 week 4

---

Naltrexone ER/Bupropion ER

Indications:

• Chronic weight management 1, 2, 3

Common Adverse Effects:

• Nausea, constipation, headache, xerostomia, insomnia 1, 2
• Elevated heart rate and blood pressure 1, 2

Contraindications:

• Uncontrolled hypertension 1, 2, 3
• Seizure disorders (bupropion lowers seizure threshold) 1, 2, 4
• Chronic opioid therapy 1, 2, 3
• Pregnancy and breastfeeding 1, 2
• Anorexia nervosa, bulimia nervosa 4
• Acute angle-closure glaucoma 1, 2

Black Box Warning: Risk of suicidal behavior/ideation in people younger than 24 years with depression 1, 2

---

Antihypertensive Medications for Hypertensive Emergencies

Labetalol (Combined Alpha-1 and Beta Blocker)

Indications:

• Hypertensive emergencies, particularly acute aortic dissection 5

Contraindications:

• Reactive airways disease or COPD 5
• Concurrent beta-blocker therapy, bradycardia, or decompensated heart failure 5
• Second- or third-degree heart block 5

Adverse Effects:

• May worsen heart failure 5
• Bradycardia (monitor closely) 5
• Higher doses may block beta-2 receptors and impact lung function 5

---

Enalaprilat (ACE Inhibitor)

Indications:

• Hypertensive emergencies, especially with high plasma renin activity 5

Contraindications:

• Pregnancy 5
• Acute MI 5
• Bilateral renal artery stenosis 5

Limitations:

• Relatively slow onset (15 minutes) 5
• Unpredictable BP response 5
• Do not use in volume-depleted patients 5

---

Phentolamine (Alpha Blocker)

Indications:

• Hypertensive emergencies from catecholamine excess: pheochromocytoma, MAOI interactions, cocaine toxicity, amphetamine overdose, clonidine withdrawal 5

Contraindications:

• Risk of increased intraocular pressure (glaucoma) 5
• Increased intracranial pressure 5
• Sulfite allergy 5

---

Anticoagulants for Cancer-Associated VTE

LMWH (Low Molecular Weight Heparin)

Indications:

• Cancer-associated venous thromboembolism 6

Contraindications:

• Absolute: Recent/acute heparin-induced thrombocytopenia (HIT) 6
• Relative: Past history of HIT 6

Use with Caution:

• Severe renal dysfunction (CrCl <30 mL/min)—consider dose adjustments or alternative therapy 6
• Anti-Xa monitoring recommended for severe renal dysfunction (though clinical relevance limited) 6

---

Direct Oral Anticoagulants (DOACs)

Contraindications:

• Stage IV chronic kidney disease: Apixaban CrCl <25 mL/min; Dabigatran, edoxaban, rivaroxaban CrCl <30 mL/min 6
• Active/clinically significant liver disease: Apixaban/edoxaban with ALT/AST >2× ULN or bilirubin >1.5× ULN; Dabigatran/rivaroxaban with ALT/AST >3× ULN 6
• Strong dual inhibitors/inducers of CYP3A4 and P-glycoprotein 6

Use with Caution:

• Urinary or GI tract lesions (associated with bleeding) 6
• Patients receiving nephrotoxic or hepatotoxic chemotherapy—monitor more closely 6

---

Key Clinical Pitfalls

1. Always verify pregnancy status before prescribing weight management medications—all are contraindicated in pregnancy 1, 2

2. Screen for thyroid cancer history before GLP-1 agonists—absolute contraindication with personal/family history of medullary thyroid cancer 1, 2

3. Assess seizure risk before naltrexone/bupropion or phentermine/topiramate—bupropion lowers seizure threshold 1, 2, 4

4. Check renal function before anticoagulants and adjust accordingly—DOACs have specific CrCl cutoffs 6

5. Avoid anticholinergic medications in elderly with cognitive impairment despite concurrent cholinesterase inhibitor use 7